Rabies Post-Exposure Prophylaxis Guidelines

Introduction to Rabies Vaccination

• The World Health Organization (WHO) recommends a 4-dose rabies vaccine schedule for post-exposure prophylaxis (PEP) in previously unvaccinated persons, with doses administered on days 0, 3, 7, and 14, along with rabies immunoglobulin (RIG) infiltrated at the wound site for optimal protection against this fatal disease 1

Post-Exposure Prophylaxis Components

• Administration of rabies immunoglobulin (RIG) for previously unvaccinated individuals 2
• Administration of rabies vaccine according to the appropriate schedule 2

Vaccination Schedules

• For previously unvaccinated persons, the WHO recommends wound cleansing, administration of 20 IU/kg body weight of Human Rabies Immunoglobulin (HRIG), and a 4-dose vaccine schedule with Human Diploid Cell Vaccine (HDCV) or Purified Chick Embryo Cell Vaccine (PCECV) on days 0, 3, 7, and 14 1
• For previously vaccinated persons, the WHO recommends wound cleansing and a 2-dose vaccine schedule with HDCV or PCECV on days 0 and 3 only 1
• For immunosuppressed patients, a 5-dose schedule is still recommended (days 0, 3, 7, 14, and 28) 1

Special Considerations

• The deltoid area is the only acceptable site for vaccination in adults and older children; for younger children, the anterolateral thigh may be used 1
• Vaccine should never be administered in the gluteal area as this may result in diminished immune response 2

Rabies Immunoglobulin Administration

• HRIG is administered only once at the beginning of PEP to provide immediate antibodies until the patient develops their own response to the vaccine 3
• If not administered at the start of vaccination, HRIG can be given up to day 7 of the PEP series 3
• HRIG should never be administered in the same syringe or anatomical site as the vaccine 3

Important Considerations

• PEP should begin immediately after exposure, regardless of the time interval between exposure and initiation of treatment 4
• Even with delayed recognition of exposure, PEP is indicated as incubation periods of greater than 1 year have been reported 4

Historical Context

• The WHO previously recommended a 6-dose vaccine schedule over 90 days (in 1977), which was later updated to a 5-dose schedule over 28 days, and finally to a 4-dose schedule over 14 days for immunocompetent individuals 1, 3, 4
• The reduction from 5 to 4 doses provides cost savings while maintaining efficacy 1

Rabies Post-Exposure Prophylaxis in Immunocompromised Patients

Introduction to Rabies Prophylaxis

• The European League Against Rheumatism (EULAR) guidelines recommend administering tetanus immunoglobulin to patients with contaminated wounds within 6 months of rituximab treatment due to reduced vaccine responses, a principle that also applies to rabies exposure, which is universally fatal without proper prophylaxis 5
• Rituximab profoundly impairs humoral immunity for up to 6 months after treatment, depleting B cells and reducing vaccine responses, making combined therapy essential for rabies post-exposure prophylaxis 5

Rationale for Combined Therapy

• Rabies immunoglobulin provides immediate passive antibody protection during the critical first 7 days before vaccine-induced antibodies develop—a period when rituximab-treated patients may fail to mount adequate responses 6
• The Centers for Disease Control and Prevention (CDC) recommends administering human rabies immunoglobulin (HRIG) at 20 IU/kg body weight as soon as possible after exposure 6

Vaccination Schedule Modification

• Immunocompromised patients, including those treated with rituximab, require the extended 5-dose vaccine schedule (days 0, 3, 7, 14, and 28) rather than the standard 4-dose regimen used for immunocompetent individuals, as recommended by the World Health Organization (WHO) 5

Specific Treatment Protocol

• The CDC recommends infiltrating up to half the HRIG dose thoroughly around and into the wound(s) if anatomically feasible, and injecting the remainder intramuscularly in the gluteal area, with HRIG given only once, at the beginning of prophylaxis 6
• The WHO recommends administering 1.0 mL rabies vaccine (HDCV or PCECV) intramuscularly on days 0, 3, 7, 14, and 28, with injection in the deltoid area for adults and older children, and the anterolateral thigh for younger children 6

Critical Timing Considerations

• The CDC recommends beginning treatment immediately after exposure, regardless of time interval, as this is a medical urgency, and even delayed treatment is indicated, as rabies incubation periods exceeding 1 year have been documented 6

Monitoring Considerations

• The CDC recommends considering serologic testing to confirm adequate antibody response given the patient's immunosuppressed state, as rituximab is associated with hypogammaglobulinemia and increased infectious complications 6

Rabies Post-Exposure Prophylaxis in Previously Vaccinated Patients

Core Principles

• The Centers for Disease Control and Prevention recommends that previously vaccinated patients who are re-exposed to rabies require only 2 booster doses of vaccine (Day 0 and Day 3) without rabies immunoglobulin (RIG), regardless of the time interval since last vaccination 7, 8, 9
• The World Health Organization suggests that previously vaccinated individuals can be considered "immunologically primed" for life, regardless of current antibody levels, and should receive a 2-dose booster regimen upon re-exposure 7, 8, 9

Management of Previously Vaccinated Patients

• The Advisory Committee on Immunization Practices states that previously vaccinated patients should receive immediate wound cleansing and a 2-dose vaccine series (Days 0 and 3) without RIG, regardless of the severity of exposure or time since last vaccination 7, 8, 9
• The Centers for Disease Control and Prevention advises that RIG is contraindicated in all previously vaccinated persons to avoid interference with anamnestic response 7, 8, 9

Special Considerations

• The National Institutes of Health recommends that immunocompromised patients require modified management, including consideration of a 5-dose vaccine schedule (Days 0, 3, 7, 14, 28) instead of the standard 2-dose regimen 10, 11
• The World Health Organization suggests that serologic testing may be considered to confirm adequate response in immunosuppressed patients 10, 11